Imago BioSciences is a San Francisco-based clinical development company that leverages the skills and extensive experience of its team and investors to focus on a small family of orphan diseases. The company is developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. Imago is evaluating Bomedemstat, an orally available, small molecule inhibitor of LSD1, as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (ET) and myelofibrosis (MF). The company's scientific efforts are aimed at developing drugs that improve the management of proliferative diseases of the bone marrow, including acute myeloid leukemia, myelodysplastic syndrome, polycythemia vera, myelofibrosis, and essential thrombocythemia.